IAR025, a novel anti-DLL3 x CD3-bispecific antibody, displays high antitumor efficacy in preclinical models of small-cell lung cancer

Abstract Small-cell lung cancer (SCLC) is one of the most aggressive subtype of lung carcinoma with limited treatment options. Delta-like ligand 3 (DLL3), a Notch ligand protein, has been an attractive target for SCLC due to its high expression on SCLC but limited expression on normal tissues. Here,...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Yang Liu, Lei Cao, Mengqiu Xu, Ninghuan Li, Jian Zhang, Mengjia Zhu, Zhihui Kuang, Huijun Sha, Min Wu, Jinling Xu, Zhihai Wu, Ye Feng, Li Li
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Springer 2026-05-01
Σειρά:	Cancer Immunology, Immunotherapy
Θέματα:	DLL3 T-cell engager Bispecific antibody Small-cell lung cancer Combination therapy
Διαθέσιμο Online:	https://doi.org/10.1007/s00262-026-04416-w
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!